Revenue Update on Geron Corporation(NASDAQ:GERN)

Geron Corporation(NASDAQ:GERN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $211.00K. Analysts estimated a revenue of $300.00K. Earnings per share were $-0.05. Analysts had estimated an EPS of $-0.07.

Geron Corporation (GERN) made into the market gainers list on Fridays trading session with the shares advancing 1.48% or 0.04 points. Due to strong positive momentum, the stock ended at $2.74, which is also near the day’s high of $2.75. The stock began the session at $2.69 and the volume stood at 6,71,601 shares. The 52-week high of the shares is $5.3 and the 52 week low is $2.3. The company has a current market capitalization of $436 M and it has 15,91,39,290 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 1, 2015, Olivia Kyusuk Bloom (EVP, Chief Financial Officer) sold 2,380 shares at $3.84 per share price.Also, On Jun 1, 2015, Melissa Kelly Behrs (EVP BD and Port&Alliance Mgmt) sold 2,380 shares at $3.84 per share price.On Mar 19, 2015, Thomas Hofstaetter (director) sold 70,000 shares at $4.10 per share price, according to the Form-4 filing with the securities and exchange commission.

Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor imetelstat in hematologic myeloid malignancies. The Company operates in one segment the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells including malignant progenitor cells to maintain telomere length which provides a capacity for limitless uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR) which binds to the telomere and a catalytic subunit (hTERT) with reverse transcriptase activity which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Geron Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Geron Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.